Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome.

Nature cell biology - 1 May 2020

Martinez-Høyer Sergio, Deng Yu, Parker Jeremy, Jiang Jihong, Mo Angela, Docking T Roderick, Gharaee Nadia, Li Jenny, Umlandt Patricia, Fuller Megan, Jädersten Martin, Kulasekararaj Austin, Malcovati Luca, List Alan F, Hellström-Lindberg Eva, Platzbecker Uwe, Karsan Aly

Abstract excerpt

Interstitial deletion of the long arm of chromosome 5 (del(5q)) is the most common structural genomic variant in myelodysplastic syndromes (MDS)1. Lenalidomide (LEN) is the treatment of choice for patients with del(5q) MDS, but half of the responding patients become resistant2 within 2 years. TP53 mutations are detected in ~20% of LEN-resistant patients3. Here we show that patients who become resistant to LEN...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomes, Human, Pair 5
Share to Core Binding Factor Alpha 2 Subunit

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down-Regulation

Share to GATA2 Transcription Factor

Share to HEK293 Cells

Share to Lenalidomide

Share to Megakaryocytes

Share to Myelodysplastic Syndromes

Source

Identifiers

PMID: 32251398
DOI: 10.1038/s41556-020-0497-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome.PMID 32251398Read ↗

A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discoverySemantic proximity Read ↗

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.Semantic proximity Read ↗

Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.Semantic proximity Read ↗

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletionSemantic proximity Read ↗

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.Semantic proximity Read ↗

PP2A: The Achilles Heal in MDS with 5q DeletionSemantic proximity Read ↗

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromesSemantic proximity Read ↗

Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid MalignanciesSemantic proximity Read ↗

Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic syndromeSemantic proximity Read ↗

Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II studySemantic proximity Read ↗

Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.Semantic proximity Read ↗

Single cell profiling of del(5q) MDS unveils its transcriptional landscape and the impact of lenalidomideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.